Metrics
1 Record Views
- Title
- 1584TiP A phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors
- Creators
- A.R. Minchom - ICRK. Culm - Clinical Development, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaL. Makris - Clinical Development, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaM.L. Johnson - Sarah Cannon Research InstituteD. Sommerhalder - Department of Oncology, NEXT OncologyTM, San Antonio, United States of AmericaJ. Henry - Sarah Cannon Research InstituteE. Garralda - Hebron UniversityJ.R. Merchan - Sylvester Comprehensive Cancer CenterM. Yang - Program Management, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaA-L. Goenaga - Clinical Development, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaD. Burzyn - Clinical Development, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaZ-Y. Yang - Research, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaR. Wei - Research, ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaJ. Mascola - ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaG. Abbadessa - ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaG. Nabel - ModeX Therapeutics, An OPKO Health Company, Weston, United States of AmericaE.E. Dumbrava - The University of Texas MD Anderson Cancer Center
- Publication Details
- Annals of oncology, Vol.36, pp.S940-S941
- Publisher
- Elsevier Ltd; AMSTERDAM
- Number of pages
- 2
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991032900656802976